{
    "name": "fluciclovine F 18",
    "comment": "Rx",
    "other_names": [
        "Axumin"
    ],
    "classes": [
        "Diagnostic Imaging Agents"
    ],
    "source": "https://reference.medscape.com/drug/axumin-fluciclovine-f-18-1000111",
    "pregnancy": {
        "common": [
            "Not indicated in females and there is not information on development outcomes in pregnant women or animals"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Not indicated for use in females and there is no information on the presence in human milk"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Hypersensitivity reactions, including anaphylaxis, may occur; emergency resuscitation equipment and personnel should be immediately available",
                "Radiation risk: Use contributes to a patientâ€™s overall long-term cumulative radiation exposure; long-term cumulative radiation exposure is associated with an increased risk for cancer; ensure safe handling to minimize radiation exposure to the patient and healthcare providers"
            ],
            "specific": [
                {
                    "type": "Misinterpretation ",
                    "description": [
                        "Image interpretation errors can occur with fluciclovine F 18 PET imaging; a negative image does not rule out the presence of recurrent prostate cancer and a positive image does not confirm the presence of recurrent prostate cancer",
                        "Performance of fluciclovine F 18 seems to be affected by PSA levels",
                        "Not specific for prostate cancer and may occur with other types of cancer and benign prostatic hypertrophy in primary prostate cancer",
                        "Clinical correlation, which may include histopathological evaluation of the suspected recurrence site, is recommended"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Injection site pain",
            "percent": null
        },
        {
            "name": "Injection site erythema",
            "percent": null
        },
        {
            "name": "Dysgeusia",
            "percent": null
        }
    ]
}